Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. The company offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.

Madrigal Pharmaceuticals, Inc.

Madrigal ($MDGL) announced an update on their ongoing clinical study. Madrigal Pharmaceuticals, Inc. is launching a Phase 2a study called “A Phase ...

Madrigal Extends Resmetirom Into Pediatric MASH, Boosting Long-Term Upside for MDGL

Madrigal Pharmaceuticals ( ($MDGL) ) has shared an update. On August 11, 2026, Madrigal Pharmaceuticals expanded its Board of Directors from eight ...

Madrigal Pharmaceuticals Adds Renowned Leader to Board

Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on Madrigal Pharmaceuticals today and set a price target of $709.00. Devarako...

Madrigal Pharmaceuticals (MDGL) Gets a Buy from Truist Financial

In a report released today, Ashwani Verma from UBS maintained a Buy rating on Madrigal Pharmaceuticals, with a price target of $669.00. According t...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MDGL	$524.87	+3.41%	307.42K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MDGL	$524.87	+3.4%	307.42K
3
4
5
6

MDGL

Get Madrigal Pharmaceuticals, Inc. Data in Excel

Get Madrigal Pharmaceuticals, Inc. Data in Excel